Association of 1,5-anhydroglucitol with cardiovascular disease and mortality

Elizabeth Selvin, Andreea Rawlings, Pamela Lutsey, Nisa Maruthur, James S. Pankow, Michael Steffes, Josef Coresh

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

In diabetes, low concentrations of the biomarker 1,5- anhydroglucitol (1,5-AG) reflect hyperglycemic excursions over the prior 1-2 weeks. To the extent that hyperglycemic excursions are important in atherogenesis, 1,5-AG may provide independent information regarding cardiovascular risk. Nonetheless, few studies have evaluated associations of 1,5-AG with long-term cardiovascular outcomes in a population-based setting. We measured 1,5-AG in 11,106 participants in the Atherosclerosis Risk in Communities (ARIC) study without cardiovascular disease at baseline (1990-1992) and examined prospective associations with coronary heart disease (n = 1,159 events), ischemic stroke (n = 637), heart failure (n = 1,553), and death (n = 3,120) over 20 years of follow-up. Cox proportional hazards models were adjusted for demographic and cardiovascular risk factors. Compared with persons with 1,5-AG ≥6 μg/mL and no history of diabetes, persons with diabetes and 1,5-AG <6.0 μg/mL had an increased risk of coronary heart disease (HR 3.85, 95% CI 3.11-4.78), stroke (HR 3.48, 95% CI 2.66-4.55), heart failure (HR 3.50, 95% CI 2.93-4.17), and death (HR 2.44, 95% CI 2.11-2.83). There was a threshold effect, with little evidence for associations at "nondiabetic" concentrations of 1,5-AG (e.g., >10 μg/mL). Associations remained but were attenuated with additional adjustment for fasting glucose or HbA1c. These data add to the growing evidence for the prognostic value of 1,5-AG for long-term complications in the setting of diabetes.

Original languageEnglish (US)
Pages (from-to)201-208
Number of pages8
JournalDiabetes
Volume65
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Cardiovascular Diseases
Mortality
Atherosclerosis
Type 1 Diabetes Mellitus
Proportional Hazards Models
Coronary Disease
1,5-anhydroglucitol
Fasting
Heart Failure
Biomarkers
Stroke
Demography
Glucose
Population

Cite this

Association of 1,5-anhydroglucitol with cardiovascular disease and mortality. / Selvin, Elizabeth; Rawlings, Andreea; Lutsey, Pamela; Maruthur, Nisa; Pankow, James S.; Steffes, Michael; Coresh, Josef.

In: Diabetes, Vol. 65, No. 1, 01.01.2016, p. 201-208.

Research output: Contribution to journalArticle

Selvin, Elizabeth ; Rawlings, Andreea ; Lutsey, Pamela ; Maruthur, Nisa ; Pankow, James S. ; Steffes, Michael ; Coresh, Josef. / Association of 1,5-anhydroglucitol with cardiovascular disease and mortality. In: Diabetes. 2016 ; Vol. 65, No. 1. pp. 201-208.
@article{8d14801693ae46c0989761219747f039,
title = "Association of 1,5-anhydroglucitol with cardiovascular disease and mortality",
abstract = "In diabetes, low concentrations of the biomarker 1,5- anhydroglucitol (1,5-AG) reflect hyperglycemic excursions over the prior 1-2 weeks. To the extent that hyperglycemic excursions are important in atherogenesis, 1,5-AG may provide independent information regarding cardiovascular risk. Nonetheless, few studies have evaluated associations of 1,5-AG with long-term cardiovascular outcomes in a population-based setting. We measured 1,5-AG in 11,106 participants in the Atherosclerosis Risk in Communities (ARIC) study without cardiovascular disease at baseline (1990-1992) and examined prospective associations with coronary heart disease (n = 1,159 events), ischemic stroke (n = 637), heart failure (n = 1,553), and death (n = 3,120) over 20 years of follow-up. Cox proportional hazards models were adjusted for demographic and cardiovascular risk factors. Compared with persons with 1,5-AG ≥6 μg/mL and no history of diabetes, persons with diabetes and 1,5-AG <6.0 μg/mL had an increased risk of coronary heart disease (HR 3.85, 95{\%} CI 3.11-4.78), stroke (HR 3.48, 95{\%} CI 2.66-4.55), heart failure (HR 3.50, 95{\%} CI 2.93-4.17), and death (HR 2.44, 95{\%} CI 2.11-2.83). There was a threshold effect, with little evidence for associations at {"}nondiabetic{"} concentrations of 1,5-AG (e.g., >10 μg/mL). Associations remained but were attenuated with additional adjustment for fasting glucose or HbA1c. These data add to the growing evidence for the prognostic value of 1,5-AG for long-term complications in the setting of diabetes.",
author = "Elizabeth Selvin and Andreea Rawlings and Pamela Lutsey and Nisa Maruthur and Pankow, {James S.} and Michael Steffes and Josef Coresh",
year = "2016",
month = "1",
day = "1",
doi = "10.2337/db15-0607",
language = "English (US)",
volume = "65",
pages = "201--208",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "1",

}

TY - JOUR

T1 - Association of 1,5-anhydroglucitol with cardiovascular disease and mortality

AU - Selvin, Elizabeth

AU - Rawlings, Andreea

AU - Lutsey, Pamela

AU - Maruthur, Nisa

AU - Pankow, James S.

AU - Steffes, Michael

AU - Coresh, Josef

PY - 2016/1/1

Y1 - 2016/1/1

N2 - In diabetes, low concentrations of the biomarker 1,5- anhydroglucitol (1,5-AG) reflect hyperglycemic excursions over the prior 1-2 weeks. To the extent that hyperglycemic excursions are important in atherogenesis, 1,5-AG may provide independent information regarding cardiovascular risk. Nonetheless, few studies have evaluated associations of 1,5-AG with long-term cardiovascular outcomes in a population-based setting. We measured 1,5-AG in 11,106 participants in the Atherosclerosis Risk in Communities (ARIC) study without cardiovascular disease at baseline (1990-1992) and examined prospective associations with coronary heart disease (n = 1,159 events), ischemic stroke (n = 637), heart failure (n = 1,553), and death (n = 3,120) over 20 years of follow-up. Cox proportional hazards models were adjusted for demographic and cardiovascular risk factors. Compared with persons with 1,5-AG ≥6 μg/mL and no history of diabetes, persons with diabetes and 1,5-AG <6.0 μg/mL had an increased risk of coronary heart disease (HR 3.85, 95% CI 3.11-4.78), stroke (HR 3.48, 95% CI 2.66-4.55), heart failure (HR 3.50, 95% CI 2.93-4.17), and death (HR 2.44, 95% CI 2.11-2.83). There was a threshold effect, with little evidence for associations at "nondiabetic" concentrations of 1,5-AG (e.g., >10 μg/mL). Associations remained but were attenuated with additional adjustment for fasting glucose or HbA1c. These data add to the growing evidence for the prognostic value of 1,5-AG for long-term complications in the setting of diabetes.

AB - In diabetes, low concentrations of the biomarker 1,5- anhydroglucitol (1,5-AG) reflect hyperglycemic excursions over the prior 1-2 weeks. To the extent that hyperglycemic excursions are important in atherogenesis, 1,5-AG may provide independent information regarding cardiovascular risk. Nonetheless, few studies have evaluated associations of 1,5-AG with long-term cardiovascular outcomes in a population-based setting. We measured 1,5-AG in 11,106 participants in the Atherosclerosis Risk in Communities (ARIC) study without cardiovascular disease at baseline (1990-1992) and examined prospective associations with coronary heart disease (n = 1,159 events), ischemic stroke (n = 637), heart failure (n = 1,553), and death (n = 3,120) over 20 years of follow-up. Cox proportional hazards models were adjusted for demographic and cardiovascular risk factors. Compared with persons with 1,5-AG ≥6 μg/mL and no history of diabetes, persons with diabetes and 1,5-AG <6.0 μg/mL had an increased risk of coronary heart disease (HR 3.85, 95% CI 3.11-4.78), stroke (HR 3.48, 95% CI 2.66-4.55), heart failure (HR 3.50, 95% CI 2.93-4.17), and death (HR 2.44, 95% CI 2.11-2.83). There was a threshold effect, with little evidence for associations at "nondiabetic" concentrations of 1,5-AG (e.g., >10 μg/mL). Associations remained but were attenuated with additional adjustment for fasting glucose or HbA1c. These data add to the growing evidence for the prognostic value of 1,5-AG for long-term complications in the setting of diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84962198344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962198344&partnerID=8YFLogxK

U2 - 10.2337/db15-0607

DO - 10.2337/db15-0607

M3 - Article

C2 - 26395741

AN - SCOPUS:84962198344

VL - 65

SP - 201

EP - 208

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 1

ER -